S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

Replimune Group (REPL) News Today

$6.45
-0.52 (-7.46%)
(As of 04/19/2024 ET)
SourceHeadline
marketbeat.com logoVontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)
marketbeat.com - April 19 at 5:37 AM
MarketBeat logoHead to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)
americanbankingnews.com - April 13 at 1:30 AM
marketbeat.com logoVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)
marketbeat.com - April 10 at 4:00 AM
globenewswire.com logoInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
globenewswire.com - April 7 at 5:00 PM
globenewswire.com logoReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 4 at 8:00 AM
bizjournals.com logoFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is ticking
bizjournals.com - March 30 at 9:59 AM
uk.investing.com logoReplimune appoints new CEO ahead of drug application
uk.investing.com - March 29 at 12:50 AM
bizjournals.com logoPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron deal
bizjournals.com - March 28 at 9:48 AM
marketwatch.com logoReplimune Names Sushil Patel as CEO in Broader Shakeup
marketwatch.com - March 26 at 12:12 PM
markets.businessinsider.com logoReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO
markets.businessinsider.com - March 26 at 12:12 PM
globenewswire.com logoReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
globenewswire.com - March 26 at 7:30 AM
marketbeat.com logoReplimune Group (NASDAQ:REPL) Stock Price Up 5.3%
marketbeat.com - March 21 at 4:24 PM
finance.yahoo.com logoREPL Apr 2024 10.000 call
finance.yahoo.com - March 16 at 12:31 PM
finance.yahoo.com logoREPL Mar 2024 10.000 put
finance.yahoo.com - March 15 at 4:28 PM
finance.yahoo.com logoReplimune to Present at the American Association for Cancer Research Annual Meeting 2024
finance.yahoo.com - March 6 at 7:31 PM
marketbeat.com logoReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Redmile Group LLC
marketbeat.com - March 5 at 8:00 PM
finance.yahoo.com logoReplimune to Present at Three Upcoming Investor Conferences
finance.yahoo.com - March 5 at 10:04 AM
marketbeat.com logoFY2024 Earnings Estimate for Replimune Group, Inc. (NASDAQ:REPL) Issued By HC Wainwright
marketbeat.com - February 19 at 2:35 AM
marketbeat.com logoReplimune Group, Inc. (NASDAQ:REPL) Holdings Decreased by Lord Abbett & CO. LLC
marketbeat.com - February 16 at 9:48 AM
markets.businessinsider.com logoPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
markets.businessinsider.com - February 15 at 6:48 PM
marketbeat.com logoReplimune Group, Inc. (NASDAQ:REPL) Expected to Post Q3 2025 Earnings of ($0.71) Per Share
marketbeat.com - February 12 at 3:22 AM
marketbeat.com logoReplimune Group (NASDAQ:REPL) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS
marketbeat.com - February 9 at 1:39 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
markets.businessinsider.com - February 9 at 7:41 AM
msn.com logoReplimune Group Is Worried About This – Should You Be Worried Too?
msn.com - February 9 at 7:41 AM
marketbeat.com logoReplimune Group (NASDAQ:REPL) Shares Up 4%
marketbeat.com - February 9 at 2:31 AM
finance.yahoo.com logoReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
finance.yahoo.com - February 8 at 11:10 AM
finance.yahoo.com logoReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
finance.yahoo.com - February 8 at 11:10 AM
investing.com logoReplimune Group Inc (REPL)
investing.com - February 8 at 12:00 AM
marketwatch.com logoDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chief
marketwatch.com - February 7 at 8:58 AM
seekingalpha.com logoReplimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
seekingalpha.com - January 23 at 1:22 PM
marketbeat.com logoTD Asset Management Inc Boosts Stake in Replimune Group, Inc. (NASDAQ:REPL)
marketbeat.com - January 18 at 5:31 AM
marketbeat.com logoReplimune Group, Inc. (NASDAQ:REPL) Sees Significant Increase in Short Interest
marketbeat.com - January 13 at 1:55 PM
finance.yahoo.com logoReplimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 28 at 9:09 AM
ca.finance.yahoo.com logoREPL Feb 2024 30.000 put
ca.finance.yahoo.com - December 17 at 8:16 PM
markets.businessinsider.com logoBalanced Outlook: Replimune’s Setbacks and Potential in Clinical Trials Justify Buy Rating
markets.businessinsider.com - December 8 at 8:32 AM
finance.yahoo.com logoAn Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued
finance.yahoo.com - December 7 at 8:51 AM
markets.businessinsider.com logoOptimistic Buy Rating on Replimune Group Focused on RP1’s Melanoma Treatment Potential and Strategic Realignment
markets.businessinsider.com - December 7 at 12:03 AM
msn.com logoReplimune shares crash as skin cancer candidate fails trial
msn.com - December 5 at 11:54 AM
msn.com logoReplimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
msn.com - December 5 at 11:54 AM
reuters.com logoReplimune's skin cancer drug fails in mid-stage study
reuters.com - December 5 at 11:54 AM
markets.businessinsider.com logoWhat's Going On With Cancer-Focused Replimune Stock Today?
markets.businessinsider.com - December 5 at 11:54 AM
finance.yahoo.com logoReplimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
finance.yahoo.com - December 5 at 11:54 AM
marketbeat.com logo
marketbeat.com - December 5 at 7:08 AM
benzinga.com logoReplimune Group Stock (NASDAQ:REPL) Dividends: History, Yield and Dates
benzinga.com - November 26 at 8:15 PM
benzinga.com logoReplimune Group Stock (NASDAQ:REPL), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 24 at 10:06 AM
markets.businessinsider.com logoAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK), Replimune Group (REPL) and Precision BioSciences (DTIL)
markets.businessinsider.com - November 8 at 10:43 PM
finance.yahoo.com logoReplimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
finance.yahoo.com - November 8 at 12:41 PM
msn.com logoReplimune Group GAAP EPS of -$0.90 misses by $0.04
msn.com - November 7 at 11:29 AM
finance.yahoo.com logoReplimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 11:29 AM
seekingalpha.com logoReplimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade)
seekingalpha.com - November 5 at 10:05 AM
Get Replimune Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

REPL Media Mentions By Week

REPL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

REPL
News Sentiment

1.63

0.49

Average
Medical
News Sentiment

REPL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

REPL Articles
This Week

1

2

REPL Articles
Average Week

Get Replimune Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:REPL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners